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Abstract
Background: Bacterial infections of the central nervous system, especially acute infections such
as bacterial meningitis require immediate, invariably empiric antibiotic therapy. The widespread
emergence of resistance among bacterial species is a cause for concern. Current antibacterial
susceptibility data among central nervous system (CNS) pathogens is important to define current
prevalence of resistance.
Methods: Antimicrobial susceptibility of pathogens isolated from CNS specimens was analyzed
using The Surveillance Database (TSN®) USA Database which gathers routine antibiotic
susceptibility data from >300 US hospital laboratories. A total of 6029 organisms derived from CNS
specimen sources during 2000–2002, were isolated and susceptibility tested.
Results:  Staphylococcus aureus (23.7%) and Streptococcus pneumoniae (11.0%) were the most
common gram-positive pathogens. Gram-negative species comprised approximately 25% of
isolates. The modal patient age was 1 or <1 year for most organisms. Prevalence of MRSA among
S. aureus from cerebrospinal fluid (CSF) and brain abscesses were 29.9–32.9%. Penicillin resistance
rates were 16.6% for S. pneumoniae, 5.3% for viridans group streptococci, and 0% for S. agalactiae.
For CSF isolates, ceftriaxone resistance was S. pneumoniae (3.5%),  E. coli (0.6%),  Klebsiella
pneumoniae (2.8%), Serratia marcescens (5.6%), Enterobacter cloacae (25.0%), Haemophilus influenzae
(0%). Listeria monocytogenes and N. meningitidis are not routinely susceptibility tested.
Conclusions: Resistance is commonly detected, albeit still at relatively low levels for key drugs
classes such as third-generation cephalosporins. This data demonstrates the need to consider
predominant resistance phenotypes when choosing empiric therapies to treat CNS infections.
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Background
Infections of the central nervous system (CNS) are poten-
tially life threatening, requiring rapid diagnosis and
immediate parenteral treatment. Nearly one in four adults
with acute bacterial meningitis will die and many survi-
vors sustain neurological deficits. Patient outcomes have
not changed since the early 1960s, despite the introduc-
tion of potent antibiotics and specialized intensive care
units [1]. Many infectious agents reach the CNS by hema-
togenous spread [2]. Pneumococcal infection may also
arise from chronic infection of the paranasal sinuses and
or middle ear. Furthermore, organisms present in the
nasopharyx may reach the CNS directly, if the dura mater
is damaged in some way following head injury or surgery
[2]. Bacterial pathogens isolated from the CNS in patients
with symptoms and diagnostic signs of bacterial meningi-
tis are Streptococcus pneumoniae, Streptococcus agalactiae and
other gram-positive cocci, Haemophilus influenzae, Neisse-
ria meningitidis, and Escherichia coli [3,4]. The epidemiol-
ogy of infectious agent varies with patient age and history
of immunization against Haemophilus influenzae type b,
meningococcus and pneumococcus. N. meningitidis is
now the most common cause of meningitis in young peo-
ple with a peak incidence at 6 months age coinciding with
the loss of maternal antibody protection [5], whilst pneu-
mococcal meningitis is the most common bacterial men-
ingitis in middle-aged and elderly patients [3,4].
The need to treat infections of the CNS immediately
requires empiric choice of an antibacterial agent. For
many years β-lactams have comprised the cornerstone of
therapy and parenteral third-generation cephalosporins
such as ceftriaxone or cefotaxime are most commonly
used [6]. Where infection is likely to have occurred from
another body site, available laboratory information on
identification and antibiogram of the organism can help
target therapy appropriately. The emergence of antibiotic
resistance in S. pneumoniae,  Staphylococcus aureus, and
enteric gram-negative bacilli documents the need for sus-
ceptibility testing to ensure appropriate antimicrobial
chemotherapy. In contrast to community respiratory
infections, for which antimicrobial susceptibility surveil-
lance studies are frequently published, few data are avail-
able to provide a current perspective on the relative
incidence and antibiotic susceptibility profiles bacterial
pathogens isolated from CNS clinical specimens. In the
routine clinical laboratory the majority of bacterial patho-
gens identified and tested are derived from the cerebrospi-
nal fluid (CSF), most likely from patients with meningitis,
and less commonly from brain abscesses, epidural
abscesses or shunt/devices.
This study was undertaken to provide a current picture of
bacterial pathogens commonly isolated from CSF and
other CNS specimens by hospital laboratories participat-
ing in The Surveillance Network (TSN) Database USA dur-
ing 2000–2002.
Methods
TSN hospital laboratory and antimicrobial susceptibility 
testing methodology
TSN Database comprises a network of hospital laborato-
ries throughout the USA. The number of participant hos-
pitals that susceptibility test bacterial isolates from CNS
specimens was 154 (2000), 155 (2001), and 153 (2002).
Susceptibility data are collected onsite by each participat-
ing laboratory as a part of their routine diagnostic suscep-
tibility testing. Methods used by these laboratories
include predominantly VITEK (bioMérieux, St. Louis,
MO) and MicroScan (Dade-Microscan, Sacramento, CA).
TSN reflects current testing in participant laboratories and
is the data reported to physicians from the respective lab-
oratories. Only susceptibility data interpreted according
to the recommendations established by the National
Committee for Clinical Laboratory Standards (NCCLS)
[7] are included in TSN. Bacterial isolates not tested for
susceptibility to antimicrobial agents are not included in
this database. In addition, TSN uses a series of quality-
control filters (i.e., critical rule sets) to screen susceptibil-
ity test results for patterns indicative of testing error and
removes suspect results from analysis for laboratory
confirmation.
Bacterial species and antimicrobials tested
We included only data on bacteria isolated from CNS clin-
ical specimens, which comprised mostly isolates from CSF
(most likely from patients with meningitis), but also iso-
lates from brain abscesses, epidural abscess and shunt/
devices. All specimens were isolated from patients during
January 1, 2000 through December 31, 2002. Data were
analyzed to determine the relative incidence and suscepti-
bility to a core set of antimicrobial agents relevant to the
treatment of CNS infections, as tested by participant clin-
ical laboratories. For each organism only antibiotics for
which susceptibility data were available were listed. Thus,
drugs listed vary per organism. No susceptibility data for
colistin for gram-negative organisms were available
through TSN. MICs were interpreted as susceptible, inter-
mediate, or resistant in TSN according to 2003 breakpoint
criteria defined by the NCCLS [8]. TSN was not able to dis-
tinguish between community-acquired or hospital-
acquired infection. In addition, TSN was not able to deter-
mine whether some isolates for which susceptibility data
were requested, were actually contaminants and not true
pathogens. Data available through TSN did not allow the
identification of H. influenzae as encapsulated or as type b
strains. No NCCLS interpretive breakpoints were defined
for N. meningitides, so few laboratories susceptibility test
this organism.Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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Results
During the 3-year time period considered, a total of 6029
organisms were isolated and susceptibility tested (Table
1). More than 90% of all organisms were derived from
CSF, the remainder from brain or epidural abscess or
shunt/device infections. The most common gram-positive
isolates were S. aureus (23.7%), S. pneumoniae (11.0%),
viridans group streptococci (VGS) (10.2%), and Enterococ-
cus species (9.8%). S. agalactiae (2.2%), coagulase-nega-
tive staphylococci (shunt/device infections only) (3.1%),
Propionibacterium acnes (2.0%) and N. meningitidis (1.0%)
were comparatively rare. E. coli (5.0%),  Enterobacter
cloacae (4.3%), Klebsiella pneumoniae (2.5%) and S. marc-
escens (2.1%) were the most common Enterobacteriaceae.
Pseudomonas aeruginosa (4.9%) was equally as common as
E. coli. Although N. meningitidis comprised just 60/6029
isolates during the 3-year period the organism was likely
under-represented because organisms included in this
study were only those accompanied by a susceptibility test
result. The modal age of patients was 1 or <1 year for all
organisms except for P. acnes (33 years), N. meningitidis (2
years) and Corynebacterium spp. (16 years). H. influenzae
was rare. For enteric bacilli, staphylococcal, P. aeruginosa
and Acinetobacter spp. a second smaller incidence peak,
primarily with isolates derived from shunt infections and
from CSF, was detected for patients >65 years (data not
shown).
Susceptibility of coagulase-positive or -negative staphylo-
coccal species (shunt isolates only) was shown (Table 2).
S. aureus was the most common pathogen tested at all
sites of infection. The proportion of S. aureus testing as
MRSA using oxacillin as marker was 29.9%, 32.9%, 15.5%
and 16.7% from CSF, brain abscess, shunt/device related
or epidural abscess specimen sources, respectively. For
coagulase-negative staphylococci 67.2% of isolates were
oxacillin-resistant. Overall for all organisms, shunt iso-
lates comprised <2.0 % of all isolates isolated and tested
from CNS sources during this time period, comprising
mainly staphylococcal species. Parenteral cephalosporins
were not active against MRSA but generally active against
>99% of oxacillin-susceptible isolates based on NCCLS
breakpoints for non-CNS infections. All staphylococci
were vancomycin susceptible. Low levels of resistance to
gentamicin, chloramphenicol, trimethoprim-sulfameth-
oxazole and rifampin were detected, although resistance
tended to be higher among coagulase-negative
staphylococci.
Table 3 shows susceptibility for the other most common
gram-positive organisms derived from CSF. VGS were iso-
lated in significant numbers only from brain abscesses.
For isolates from CSF specimens, resistance among ente-
rococci varied by species. The prevalence of vancomycin
resistance among E. faecium was 61.5% and the preva-
lence of resistance to ampicillin, the class representative
Table 1: Relative incidence of bacterial species isolated from central nervous system specimens. TSN Database USA 2000–2002.
Organism Number of organisms Percentage of total Patient age range (year) Modal Patient age (year)
Staphylococcus aureus 1426 23.7 <1 – >90 <1
Streptococcus pneumoniae 661 11.0 <1 – >90 1
Viridans group 
streptococci
612 10.2 <1 – 88 <1
Enterococcus spp. 590 9.8 <1 – >90 <1
Escherichia coli 302 5.0 <1 – 89 <1
Pseudomonas aeruginosa 295 4.9 <1 – >90 <1
Enterobacter cloacae 260 4.3 <1 – 84 <1
Coagulase-negative 
staphylococci a
184 3.1 <1–>90 1
Acinetobacter baumannii 162 2.7 <1 – 84 <1
Klebsiella pneumoniae 151 2.5 <1 – 83 <1
Streptococcus agalactiae 131 2.2 <1 – 83 <1
Serratia marcescens 127 2.1 <1 – 85 <1
Proprionibacterium acnes 118 2.0 <1 – 82 33
Enterobacter aerogenes 103 1.7 <1 – 84 <1
Haemophilus influenzae 75 1.2 <1 – >90 <1
Klebsiella oxytoca 62 1.0 <1 – 69 <1
Neisseria meningitidis 60 1.0 <1 – 70 2
Corynebacterium spp. 58 1.0 <1 – 87 16
Other b 652 10.8 <1 – >90 <1
Total 6029 100
aCoagulase-negative staphylococci only includes isolates associated with shunt/device infections bOrganisms isolated at a frequency of <0.5%.Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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for amino-penicillins, was 84.9%. Significantly less resist-
ance was detected among E. faecalis isolates. Ceftriaxone
resistance rates were recorded in 9.1% of VGS, 3.5% of S.
pneumoniae, and 0% of S. agalactiae (data not tabulated),
although more active than cefotaxime. Penicillin resist-
ance was recorded in 5.3% of VGS, 16.6% of S. pneumo-
niae, and 0% of S. agalactiae (data not tabulated). For S.
pneumoniae meropenem resistance was recorded in 7.9%
of isolates but was not detected in other streptococcal spe-
cies. Resistance to chloramphenicol among streptococci
was uncommon (3–3.9%). Rifampin resistance ranged
from 17.2% to 30.0% among enterococci and was not
recorded among S. pneumoniae. TMP-SMX resistance was
common among S. pneumoniae. Resistance in VGS from
brain abscesses to ceftriaxone and penicillin was recorded
as 3.0% and 1.4%, respectively, with organisms generally
more susceptible than those isolated from CSF specimens.
With the exception of a small number of VGS from CSF
specimens, all streptococci were susceptible to
levofloxacin.
Susceptibility of predominant gram-negative species iso-
lated from CSF specimens was shown (Table 4). Gram-
negative isolates were rarely isolated from brain abscess,
shunt, or epidural abscess specimens. No meropenem
resistance was detected in Enterobacteriaceae but detected
in 10.3% and 23.5% of P. aeruginosa and A. baumanii.
Resistance to amikacin was rare among Enterobacteriaceae
and was 4.9% for P. aeruginosa and 17.9% for Acinetobacter
spp. Among enteric organisms the prevalence of resistance
was low against ceftriaxone for E. coli (0.6%), E. aerogenes
(1.6%), and K. pneumoniae (2.8%) and were higher for S.
marcescens  (5.6%),  K. oxytoca (13.3%), and E. cloacae
(25.0%). Resistance to ceftazidime was 1.4% and 18.0 %
in E. coli and K. pneumoniae, respectively. For Enterobacte-
riaceae, aztreonam resistance ranged from 1.5% in E. coli
to 26.5% in E. cloacae. Levofloxacin resistance rates were
uncommon in all Enterobacteriaceae tested apart from K.
pneumoniae (9.2%). For P. aeruginosa the prevalence of
ceftazidime and amikacin resistance was 11.0% and 4.9%,
respectively and for A. baumanii 38.7% and 17.9%, respec-
tively. For both of these organisms relatively high resist-
ance to levofloxacin was detected and meropenem was
the most active β-lactam compound tested with resistance
recorded as 10.3% and 23.5%, respectively. Approxi-
mately 24.0% of H. influenzae produced β-lactamase as
estimated by ampicillin resistance. All H. influenzae iso-
lates tested were susceptible to cefotaxime, ceftriaxone,
and levofloxacin.
Discussion
Vaccination against infections with H. influenzae and N.
meningitidis  has significantly reduced the incidence of
community-acquired infections caused by these organ-
Table 2: Susceptibility of staphylococcal species isolated from cerebrospinal fluid, brain abscess, shunt related and epidural specimen 
sources. TSN Database USA 2000–2002.
Cerebrospinal fluid Brain abscess Shunt related Epidural abscess
Organism Antimicrobial Total n %Sa %R Total n %S %R Total n %S %R Total n %S %R
Staphylococcus aureus cefotaxime 270 74.8 25.2 12 75.0 25.0 10 90.0 10.0 NAb NA NA
ceftriaxone 273 71.8 27.8 13 76.9 23.1 18 88.9 11.1 NA NA NA
levofloxacin 666 73.1 22.8 48 72.9 27.1 33 97.0 3.0 83 79.5 18.1
chloramphenicol 277 95.3 1.4 6 100 0 9 88.9 0 NA NA NA
gentamicin 941 93.0 6.8 65 93.8 4.6 53 94.3 5.7 38 97.4 2.6
oxacillin 1189 70.1 29.9 76 67.1 32.9 71 84.5 15.5 108 83.3 16.7
rifampin 851 96.9 2.5 51 100 0 48 91.7 6.3 24 100 0
TMP-SMXc 1058 95.9 4.1 72 94.4 5.6 47 100 0 101 96.0 4.0
vancomycin 1150 100 0 76 100 0 58 100 0 102 100 0
Coagulase-negative 
staphylococci 
(shunt-related only)
cefotaxime NDd ND ND ND ND ND 32 34.4 65.6 ND ND ND
ceftriaxone ND ND ND ND ND ND 37 35.1 64.9 ND ND ND
levofloxacin ND ND ND ND ND ND 75 82.7 5.3 ND ND ND
chloramphenicol ND ND ND ND ND ND 22 95.5 0 ND ND ND
gentamicin ND ND ND ND ND ND 124 75.8 22.6 ND ND ND
oxacillin ND ND ND ND ND ND 183 32.8 67.2 ND ND ND
rifampin ND ND ND ND ND ND 108 92.6 6.5 ND ND ND
TMP-SMX ND ND ND ND ND ND 114 77.2 22.8 ND ND ND
vancomycin ND ND ND ND ND ND 161 100 0 ND ND ND
aNCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]bNA – <5 organisms tested cTMP-SMX – 
Trimethoprim-sulfamethoxazole dND – No dataAnnals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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isms [9,10]. Additionally, the growing use of the pneuo-
coccocal conjugate vaccine has also had a positive impact
on the incidence of pneumococcal meningitis [11,12].
Since clinicians will likely initiate antimicrobial therapy
prior to the microbiological characterization of the infect-
ing agent, with the reduction in incidence of some species
and increased resistance in others, resistance surveillance
plays an important role in helping to understand trends in
predominant pathogens and the impact of resistance on
empiric choice [13]. The TSN database was not able to dis-
criminate between specific diagnoses; however, consider-
ing bacterial pathogens isolated from specific specimen
sources provides a contemporary picture of current sus-
ceptibility to commonly considered antimicrobial agents
for the most prevalent organisms encountered at these
sites of infections.
For the most significant community-acquired pathogens,
this study showed similarities between epidemiological
trends recently published. For meningitis in the USA, a
report by Schuchat et al., 1997, recorded a significant shift
from 15 months to 25 years, in the median age of patients
with meningitis due to the five major pathogens: H. influ-
enzae, S. pneumoniae, N. meningitidis, S. agalactiae, and L.
monocytogenes [3]. Overall including all specimen sources
together, although the majority of isolates were derived
from the CSF, our study showed that isolates were derived
from a wide spectrum of patient ages. However with few
exceptions, the modal age of patients was ≤1 year old,
demonstrating the burden of infection to be with infants
and with a second peak for patients >65 years [3].
Table 3: Susceptibility of gram-positive organisms isolated from cerebrospinal fluid and brain abscess specimen sources. TSN Database 
USA 2000–2002.
Cerebrospinal fluid Brain abscess
Organism Antimicrobial Total n %Sa %R Total n %S %R
Enterococcus faecalis ampicillin 229 98.7 1.3 NDb ND ND
chloramphenicol 79 79.7 15.2 ND ND ND
levofloxacin 136 81.6 18.4 ND ND ND
penicillin 165 99.4 0.6 ND ND ND
rifampin 58 58.6 17.2 ND ND ND
vancomycin 239 98.7 1.3 ND ND ND
Enterococcus faecium ampicillin 93 15.1 84.9 ND ND ND
chloramphenicol 54 92.6 0 ND ND ND
levofloxacin 56 12.5 85.7 ND ND ND
penicillin 50 22.0 78.0 ND ND ND
rifampin 30 56.7 30.0 ND ND ND
vancomycin 96 38.5 61.5 ND ND ND
Viridans group 
Streptococci
ampicillin 95 62.1 6.3 10 90.0 0
cefotaxime 174 85.1 9.8 32 96.9 3.1
ceftriaxone 220 87.3 9.1 33 93.9 3.0
chloramphenicol 100 96.0 3.0 14 92.9 0
meropenem 19 100 0 13 100 0
levofloxacin 90 96.7 1.1 24 100 0
penicillin 437 63.2 5.3 72 97.2 1.4
vancomycin 396 100 -e 44 100 0
Streptococcus 
pneumoniae
cefotaxime 313 80.5 7.7 (19.5 NSc)N D N D N D
ceftriaxone 404 85.4 3.5 (14.6 NS) ND ND ND
chloramphenicol 180 96.1 3.9 (3.9 NS) ND ND ND
meropenem 76 78.9 7.9 (21.1 NS) ND ND ND
levofloxacin 283 100 0 ND ND ND
penicillin 565 59.5 16.6 (40.5 NS) ND ND ND
rifampin 70 100 0 ND ND ND
TMP-SMXd 233 65.2 27.5 (34.8 NS) ND ND ND
vancomycin 453 100 - ND ND ND
aNCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]bND – No data cNS – Percent non-susceptible 
(including intermediate and resistant isolates) dTMP-SMX – Trimethoprim-sulfamethoxazole eDashed line indicates that NCCLS breakpoints do not 
currently exist to interpret results as resistantAnnals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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Table 4: Susceptibility of gram-negative organisms isolated from cerebrospinal fluid specimen sources. TSN Database USA 2000–2002
Organism Antimicrobial Total n %Sa %R
Escherichia coli amikacin 164 98.8 0
ampicillin 267 44.2 54.7
aztreonam 137 96.4 1.5
cefotaxime 168 98.2 0
ceftazidime 210 98.1 1.4
ceftriaxone 180 97.8 0.6
gentamicin 260 93.5 5.4
levofloxacin 198 97.5 2.5
meropenem 76 100 0
piperacillin 188 50.0 38.8
TMP-SMXb 252 77.0 23.0
Pseudomonas aeruginosa amikacin 184 92.9 4.9
aztreonam 133 67.7 15.0
cefotaxime 111 9.0 49.5
ceftazidime 236 80.1 11.0
ceftriaxone 116 6.0 61.2
gentamicin 251 80.9 11.2
levofloxacin 174 82.2 11.5
meropenem 97 84.5 10.3
piperacillin 198 82.8 17.2
TMP-SMX 128 0.8 99.2
Enterobacter cloacae amikacin 160 98.8 0
ampicillin 229 2.2 91.7
aztreonam 147 65.3 26.5
cefotaxime 154 63.6 28.6
ceftazidime 196 67.3 29.6
ceftriaxone 184 70.7 25.0
gentamicin 227 95.2 4.8
levofloxacin 176 96.0 4.0
meropenem 79 100 0
piperacillin 168 64.9 28.0
TMP-SMX 220 93.2 6.8
Acinetobacter baumannii amikacin 112 75.0 17.9
aztreonam 88 8.0 73.9
cefotaxime 102 21.6 54.9
ceftazidime 142 48.6 38.7
ceftriaxone 119 25.2 53.8
gentamicin 143 61.5 38.5
levofloxacin 106 53.8 43.4
meropenem 68 75.0 23.5
piperacillin 111 40.5 40.5
TMP-SMX 140 54.3 45.7
Klebsiella pneumoniae amikacin 95 92.6 0
ampicillin 129 0 98.4
aztreonam 70 84.3 14.3
cefotaxime 94 87.2 3.2
ceftazidime 111 76.6 18.0
ceftriaxone 108 84.3 2.8
gentamicin 131 87.8 8.4
levofloxacin 98 88.8 9.2
meropenem 47 100 0
piperacillin 102 65.7 26.5
TMP-SMX 133 83.5 16.5
Serratia marcescens amikacin 71 95.8 2.8
ampicillin 104 5.8 92.3
aztreonam 55 87.3 7.3
cefotaxime 70 80.0 8.6
ceftazidime 86 93.0 4.7
ceftriaxone 71 91.5 5.6Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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The low comparative prevalence of H. influenzae indicates
the success of the Hib vaccination program, which has
largely removed this organism from its once ubiquitous
role in meningeal infection in children in the United
States [14]. Schuchat et al. also reported L. monocytogenes
to be associated with infections in children <1 year old
and increases in incidence in patients older than 65 years.
In this current study, the relative importance of both L.
monocytogenes and N. meningitidis in infection cannot be
measured since the organisms were rarely tested for anti-
microbial susceptibilities in hospital laboratories and
thus not reported through the system. Additionally, no
NCCLS breakpoints have been defined for N. meningitidis
[9]. Invasive pneumococcal disease is a significant cause
of morbidity and mortality in the USA, especially for the
young and old. Schuchat et al. demonstrated S. pneumo-
niae to infect patients of all ages, the same trend observed
in our study. We also showed that with the exception of
staphylococci, S. pneumoniae was the most common path-
ogen reported. A previous report showed 4.4% of cases of
invasive pneumococcal disease associated with meningitis
[3]. Further analysis of TSN showed that during the study
period laboratories reported 661 non-repeat CNS pneu-
mococcal isolates and 9868 non-repeat pneumococcal
blood isolates, corresponding to a 6–7% rate of patients
with invasive infections likely to be associated with pneu-
mococcal meningitis, close to the 4–5% reported in 1995
[3]. This study also showed Enterobacteriaceae to be more
common in hospital-acquired meningeal infections. S.
aureus  was by far the most frequently encountered
pathogen in participant hospital laboratories, in this
study together comprising 23.7% of isolates and the only
isolate encountered at all specimen source sites consid-
ered. A previous French study showed S. aureus to be the
most common pathogen associated with neurosurgical
infections [15]. In addition to the staphylococci, Entero-
coccus spp., P. aeruginosa, P. acnes, and Enterobacteriaceae
were most commonly isolated from infants (<1 year old),
although the median age also demonstrates the common
involvement in adult patients. Together these organisms
gentamicin 108 95.4 2.8
levofloxacin 80 98.8 1.3
meropenem 43 100 0
piperacillin 81 72.8 21.0
TMP-SMX 105 95.2 4.8
Enterobacter aerogenes amikacin 60 100 0
ampicillin 87 5.7 87.4
aztreonam 42 73.8 11.9
cefotaxime 54 74.1 1.9
ceftazidime 78 73.1 17.9
ceftriaxone 63 84.1 1.6
gentamicin 81 100 0
levofloxacin 51 100 0
meropenem 22 100 0
piperacillin 64 68.8 14.1
TMP-SMX 85 100 0
Haemophilus influenzae ampicillin 61 72.1 24.6
cefotaxime 27 100 -d
ceftazidime NAc NA NA
ceftriaxone 54 100 -
levofloxacin 10 100 -
TMP-SMX 32 87.5 9.4
Klebsiella oxytoca amikacin 37 100 0
ampicillin 52 3.8 86.5
aztreonam 34 76.5 17.6
cefotaxime 37 81.1 16.2
ceftazidime 44 81.8 18.2
ceftriaxone 45 84.4 13.3
gentamicin 51 96.1 3.9
levofloxacin 39 100 0
meropenem 23 100 0
piperacillin 38 73.7 21.1
TMP-SMX 51 80.4 19.6
aNCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]bTMP-SMX – Trimethoprim-sulfamethoxazole cNA 
<5 organisms tested dDashed line indicates that NCCLS breakpoints do not currently exist to interpret results as resistant
Table 4: Susceptibility of gram-negative organisms isolated from cerebrospinal fluid specimen sources. TSN Database USA 2000–2002 Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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are becoming common causes of meningeal infection,
often as a complication in immunocompromised
patients, in patients with septicemia, following head
trauma, or surgical procedures especially those involving
CSF shunts.
The relatively high incidence of oxacillin-resistant S.
aureus from CSF and brain abscesses negatively impacts
the empiric utility of isoxazolyl penicillins reaffirming the
need to include anti-MRSA coverage for patients with
meningitis and brain abscesses, unless subsequent suscep-
tibility testing shows the organism to be oxacillin suscep-
tible. Even among isolates from shunts and epidural
abscesses the 15–17% incidence of oxacillin resistance
likely mandates the use of empiric therapies such as van-
comycin that cover MRSA. However, it is important to
note that these levels are lower than the national rates of
MRSA of 51.2% (36,181/70,693) recorded among the
general inpatient population in the USA during 2002
[TSN Database USA, Focus Technologies Inc. Data on
file]. Susceptibility test results for MRSA to linezolid, a
recently FDA-approved oxazolidinone-class antibiotic,
and daptomycin, a recently approved glycopeptide-class
antibiotic, were not available at the time of this study,
although neither drugs have indications to treat infections
of the central nervous system. Interestingly, despite an
overall increase in the incidence of MRSA in hospitals in
recent years in both inpatient and outpatient environ-
ments [16] an increased incidence of multi-drug suscepti-
ble MRSA, especially in community infections, has also
been reported [17], which may augment the use of other
compounds such as clindamycin in therapy. For shunt/
device related infections, the high rates of oxacillin resist-
ance recorded among coagulase-negative staphylococci
indicate the need to consider appropriate therapies to
cover these phenotypes. For both staphylococcal species
resistance to rifampin, occasionally used in combination,
was rare, comprising 0–6.5% of isolates from each spe-
cies, respectively. Despite reports of vancomycin resist-
ance in coagulase-negative staphylococci [18] and more
recently  S. aureus [19,20], during the three-year study
period, no vancomycin non-susceptible isolates of either
species were recorded. Vancomycin also plays an impor-
tant role in the treatment of other resistant gram-positive
infections, most importantly those caused by penicillin-
resistant  S. pneumoniae (penicillin MIC >2 µg/ml), for
which no resistance was documented. Of the 661 isolates
reported during the study period (11.0% of total), 16.6%
and 23.9% tested as penicillin-resistant and -intermedi-
ate, respectively. For meningitis caused by pneumococci
and in situations where the incidence of penicillin resist-
ance is significant, the use of third-generation, parenteral
cephalosporins such as ceftriaxone or cefotaxime is a
more suitable empiric therapy. The percentage resistance
to third-generation cephalosporins for the common strep-
tococcal isolates from CSF, likely involved in meningeal
infection, remained low (3.5% for ceftriaxone); however,
concerns about resistance in CNS infections are sufficient
to prompt recommendations to combine ceftriaxone or
cefotaxime with vancomycin for empiric therapy of pneu-
mococcal CNS infections. The reported rate of resistance
in S. pneumoniae to ceftriaxone and cefotaxime reflects the
higher breakpoints used compared to those used for non-
meningeal pneumococcal isolates, reflecting the lower
antibiotic concentrations achievable in the CNS. Impor-
tantly in addition to streptococci, 100% of H. influenzae
tested as susceptible to ceftriaxone and cefotaxime. As
such the utility of this drug class in community or hospital
acquired infections meningeal infections with these
organisms remains unchanged.
The incidence of vancomycin-resistant phenotypes
among enterococci, organisms not commonly associated
with meningeal infections, is alarming if the organisms
isolated were colonizers. Importantly, the majority of
glycopeptide-resistant isolates are E. faecium, which are
less common than E. faecalis.
Our study showed resistance to amikacin remained very
low (0–2.8%) among Enterobacteriaceae and low among
Acinetobacter  spp. and P. aeruginosa (17.9% and 4.9%,
respectively), although the utility of this agent is limited
in CNS infections. Importantly, bearing in mind their role
in empiric therapy for meningitis, resistance to third-gen-
eration cephalosporins such as ceftriaxone, remained very
uncommon in the common enterobacterial species (E. coli
0.6%,  K. pneumoniae 2.6%, and S. marcescens 5.2%).
Resistance to ceftazidime in these species was somewhat
higher than for ceftriaxone. Together these data suggest
that the incidence of extended spectrum β-lactamases or
AmpC β-lactamase producers still remains low, prevent-
ing a reliance on the use of carbapenems such as mero-
penem to which resistance among gram-negative
organisms remains very rare. Changing patterns of antimi-
crobial resistance and the involvement of unusual species
because of the increase in immunocompromised patients,
has created renewed interest in drugs such as fluoroqui-
nolones, which have previously been shown to have good
potential for treating meningitis [21], although currently
do not have an indication for use in CNS infection or in
pediatrics. Nevertheless using levofloxacin as a marker for
this drug class activity, streptococci, several species of
Enterobacteriaceae and H. influenzae were highly suscepti-
ble using current breakpoint guidelines.
Conclusions
Several factors influence the choice of antibacterial agent
in the treatment of bacterial meningitis. Perhaps most
importantly is the degree at which the agent is able to pen-
etrate into the CSF, which to a large extent depends on theAnnals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/3
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status of the blood brain barrier [22]. Low toxicity and
rapid bactericidal activity are also important factors to
consider and for these reasons β-lactams have always
played a key role in treating infections of the CNS. Our
study showed that for the treatment of the most important
pathogens associated with acute community-acquired
meningitis including S. pneumoniae,  H. influenzae, and
group B streptococci, while resistance to penicillin deriva-
tives is relatively common, resistance to third-generation
cephalosporins remains uncommon. Similarly, third-gen-
eration cephalosporins also retain good activity against
the most common species of Enterobactericeae. For infec-
tions in which oxacillin-resistant staphylococcal species
are suspected or shown microbiologically, vancomycin
remains as a frontline agent to which no resistant isolates
were detected through 2002. While national surveillance
studies such as this are able to detect general trends in sus-
ceptibility, this information combined with local institu-
tional level data play a critical role in choosing empiric
therapies.
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